首页> 美国卫生研究院文献>other >First-in-human Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat an Oral Histone Deacetylase Inhibitor in Patients with Advanced Solid Tumors

【2h】

First-in-human Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat an Oral Histone Deacetylase Inhibitor in Patients with Advanced Solid Tumors

机译：Resminostat（一种口服组蛋白去乙酰化酶抑制剂）在晚期实体瘤患者中的首次人体药代动力学和药效动力学I期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

PurposeThis first-in-human dose-escalating trial investigated the safety, tolerability, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), pharmacokinetics and pharmacodynamics of the novel histone deacetylase (HDAC) inhibitor resminostat in patients with advanced solid tumors.

机译：目的这项首次人类递增剂量试验研究了新型组蛋白脱乙酰酶（HDAC）抑制剂Resminostat在晚期实体瘤患者中的安全性，耐受性，最大耐受剂量（MTD），剂量限制性毒性（DLT），药代动力学和药效学。

著录项

期刊名称 other
作者
André T. Brunetto; Joo Ern Ang; Rohit Lal; David Olmos; L. Rhoda Molife; Rebecca Kristeleit; Ann Parker; Isabel Casamayor; Muyibat Olaleye; Anna Mais; Bernhard Hauns; Vera Strobel; Bernd Hentsch; Johann S. de Bono;
展开▼
作者单位

展开▼
年(卷),期 -1(19),19
年度 -1
页码 5494–5504
总页数 20
原文格式 PDF
正文语种
中图分类
关键词
resminostat histone deacetylase inhibitor Phase I trial;

机译：Resminostat;组蛋白脱乙酰基酶抑制剂;I期试验;

相似文献

外文文献
中文文献
专利

1. First-in-human, pharmacokinetic and pharmacodynamic phase i study of resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors [J] . BrunettoA.T., AngJ.E., LalR., Clinical cancer research: an official journal of the American Association for Cancer Research . 2013,第19期

机译：口服组蛋白脱乙酰基酶抑制剂resminostat在晚期实体瘤患者中的首次人体，药代动力学和药效学研究
2. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. [J] . de-Bono JS, Kristeleit R, Tolcher A, Clinical cancer research: an official journal of the American Association for Cancer Research . 2008,第20期

机译：LAQ824（具有热休克蛋白90抑制特性的异羟肟酸酯组蛋白脱乙酰基酶抑制剂）在晚期实体瘤患者中的第一阶段药代动力学和药效学研究。
3. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours [J] . A R A Razak, S J Hotte, L L Siu, British Journal of Cancer . 2011,第5期

机译：口服组蛋白脱乙酰基酶（HDAC）抑制剂SB939在晚期实体瘤患者中的I期临床，药代动力学和药效学研究
4. Synthesis, Evaluation and Molecular Modeling Study of L-2-amino-7/8-Bromoalkanoic Acid Derivatives as Histone Deacetylase Inhibitors [C] . Dawei Huang, Xiaohui Li, Zhilong Xiu, Chinese international peptide symposium . 2011

机译：L-2-氨基-7 / 8-溴烷酸衍生物作为组蛋白脱乙酰酶抑制剂的合成，评价和分子建模研究
5. Evaluation of the pharmacokinetic-pharmacodynamic relationship, metabolism and plasma protein binding of the novel antitumor agent, 2-methoxyestradiol (2ME2), following oral administration in patients with solid tumors. [D] . Lakhani, Nehal Jagdish. 2005

机译：实体瘤患者口服后评估新型抗肿瘤药2-甲氧基雌二醇（2ME2）的药代动力学与药效关系，代谢和血浆蛋白结合。
6. Phase I clinical pharmacokinetic and pharmacodynamic study of SB939 an oral histone deacetylase (HDAC) inhibitor in patients with advanced solid tumours [O] . A R A Razak, S J Hotte, L L Siu, 2011

机译：口服组蛋白脱乙酰基酶（HDAC）抑制剂SB939对晚期实体瘤患者的I期临床药代动力学和药效学研究
7. Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors [O] . Johann S. de Bono, Rebecca Kristeleit, Anthony Tolcher, 2008

机译：LaQ824的I相药代动力学和药效学研究，一种羟肟酸盐组蛋白脱乙酰酶抑制剂，具有热休克蛋白-90抑制型材，患有先进的实体瘤患者

First-in-human Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat an Oral Histone Deacetylase Inhibitor in Patients with Advanced Solid Tumors

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅